Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
Jaguar Health (NASDAQ:JAGX) is seeking a partner to develop and commercialize NP300, a second-generation antisecretory drug candidate for treating general diarrhea in dogs. NP300, derived from the Croton lechleri tree, has shown safety in dogs and shares similarities with Canalevia-CA1, the company's conditionally approved drug for chemotherapy-induced diarrhea. With approximately 6 million annual cases of acute and chronic diarrhea in dogs seen by U.S. veterinarians and no FDA-approved drugs for general canine diarrhea, the company aims to address this unmet need in the veterinary market.
Jaguar Health (NASDAQ:JAGX) sta cercando un partner per sviluppare e commercializzare NP300, un candidato farmaceutico antisecretivo di seconda generazione per il trattamento della diarrea generale nei cani. NP300, derivato dall'albero Croton lechleri, ha dimostrato sicurezza nei cani e presenta somiglianze con Canalevia-CA1, il farmaco approvato con riserva dell'azienda per la diarrea indotta da chemioterapia. Con circa 6 milioni di casi annuali di diarrea acuta e cronica nei cani riscontrati dai veterinari negli Stati Uniti e nessun farmaco approvato dalla FDA per la diarrea canina generale, l'azienda mira a soddisfare questo bisogno insoddisfatto nel mercato veterinario.
Jaguar Health (NASDAQ:JAGX) está buscando un socio para desarrollar y comercializar NP300, un candidato a fármaco antisecretor de segunda generación para tratar la diarrea general en perros. NP300, derivado del árbol Croton lechleri, ha demostrado ser seguro en perros y comparte similitudes con Canalevia-CA1, el fármaco aprobado condicionalmente por la empresa para la diarrea inducida por quimioterapia. Con aproximadamente 6 millones de casos anuales de diarrea aguda y crónica en perros atendidos por veterinarios en EE. UU. y sin fármacos aprobados por la FDA para la diarrea canina general, la empresa busca abordar esta necesidad no satisfecha en el mercado veterinario.
재규어 헬스 (NASDAQ:JAGX)는 개의 일반적인 설사를 치료하기 위해 NP300라는 2세대 항비밀 약물 후보를 개발하고 상용화할 파트너를 찾고 있습니다. NP300은 크로톤 레클레리 나무에서 파생되었으며, 개에서 안전성을 입증하였고, 항암치료로 인한 설사를 위해 회사가 조건부 승인한 약물인 Canalevia-CA1과 유사성을 가지고 있습니다. 미국 수의사들이 겪는 급성 및 만성 설사 사례가 연간 약 600만 건에 이르고, 일반 개 설사를 위한 FDA 승인 약물이 없는 상황에서, 회사는 수의학 시장의 이 unmet need에 대응하는 것을 목표로 하고 있습니다.
Jaguar Health (NASDAQ:JAGX) recherche un partenaire pour développer et commercialiser NP300, un candidat médicament antisecrétoire de seconde génération pour traiter la diarrhée générale chez les chiens. NP300, dérivé de l'arbre Croton lechleri, a montré sa sécurité chez les chiens et présente des similitudes avec Canalevia-CA1, le médicament approuvé sous conditions par l'entreprise pour la diarrhée induite par la chimiothérapie. Avec environ 6 millions de cas annuels de diarrhée aiguë et chronique chez les chiens traités par des vétérinaires aux États-Unis et sans médicaments approuvés par la FDA pour la diarrhée canine générale, l'entreprise vise à répondre à ce besoin non satisfait sur le marché vétérinaire.
Jaguar Health (NASDAQ:JAGX) sucht einen Partner, um NP300, einen Wirkstoffkandidaten der zweiten Generation zur Behandlung von allgemeinem Durchfall bei Hunden, zu entwickeln und zu vermarkten. NP300, abgeleitet vom Croton lechleri-Baum, hat sich bei Hunden als sicher erwiesen und weist Ähnlichkeiten mit Canalevia-CA1 auf, dem bedingt genehmigten Medikament des Unternehmens zur Behandlung von durch Chemotherapie induziertem Durchfall. Mit ungefähr 6 Millionen jährlichen Fällen von akutem und chronischem Durchfall bei Hunden, die von US-Tierärzten behandelt werden, und ohne von der FDA genehmigte Medikamente für allgemeinen Hundedurchfall, zielt das Unternehmen darauf ab, dieses unbefriedigte Bedürfnis auf dem veterinärmedizinischen Markt zu decken.
- Canalevia-CA1 received extension of conditional FDA approval
- Large market potential with 6 million annual cases of canine diarrhea in the US
- No current FDA-approved competition for general canine diarrhea treatment
- Requires external partnership for development and commercialization funding
- Product still in development phase with no guaranteed approval
Insights
This business development initiative for NP300 represents a strategic opportunity in the $11.5B veterinary medicine market. The target indication addresses a significant unmet need, with approximately 6 million annual cases of canine diarrhea in the U.S. The lack of FDA-approved treatments creates a clear market opportunity. The company's track record with Canalevia-CA1 and the sustainable sourcing from Croton lechleri trees adds credibility to the development program.
The potential partnership structure, offering U.S. commercial rights in exchange for development funding, could significantly reduce Jaguar's financial burden while maintaining global opportunities. However, given JAGX's micro-cap status (
Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs
Canalevia®-CA1, Jaguar's first-generation antisecretory drug for the treatment of chemotherapy-induced diarrhea in dogs, has received extension of conditional approval by FDA
Jaguar is attending the December 3-5 Pet Connect conference and is available for NP300 partnership discussions at the event
SAN FRANCISCO, CA / ACCESSWIRE / November 22, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar"), under its Jaguar Animal Health tradename for the veterinary market, today announced that it is seeking a partner to fund and execute the development and commercialization of NP300, the company's prescription drug candidate for the treatment of general, non-infectious diarrhea in dogs, in exchange for commercial rights to the product in the U.S.
NP300 is a novel antisecretory drug with a similar mechanism of action to Canalevia®-CA1 (crofelemer delayed-release tablets), the company's conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs. NP300 has demonstrated safety in dogs and is sustainably derived from the Croton lechleri tree, the same source as that for crofelemer.
"We look forward to evaluating NP300 for treatment of general, non-infectious diarrhea in dogs, and to identifying a partner organization to fund and execute development and commercialization of the product," said David Sesin, PhD, Jaguar's Chief Manufacturing Officer. "We've been pleased with the marketplace reception of crofelemer for treatment of CID in dogs, and believe there is clearly an unmet need for a product to treat general, non-infectious diarrhea in dogs as well. We estimate that U.S. veterinarians see approximately six million annual cases of acute and chronic diarrhea in dogs. We are attending the Pet Connect conference, which takes place December 3-5, 2024 in Hollywood, California, with the goal of speaking with potential partners about NP300."
Diarrhea is one of the most common reasons for veterinary office visits for dogs and is the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drug to treat canine diarrhea. According to the American Veterinary Medical Association, there were an estimated 89.7 million dogs in the United States in 2024, with nearly half (
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram
Important Safety Information About Canalevia-CA1
For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.
Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that company personnel will attend the December 3-5, 2024 Pet Connect conference, and Jaguar's expectation that it may identify a partner organization to fund and execute development and commercialization of NP300. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Source: Jaguar Health, Inc.
Contact:
hello@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on accesswire.com
FAQ
What is Jaguar Health's NP300 drug candidate for dogs?
How many cases of dog diarrhea are seen annually by US veterinarians according to JAGX?
Are there any FDA-approved drugs for treating general diarrhea in dogs?
